Endorectal MRI of prostate cancer: Incremental prognostic importance of gross locally advanced disease

American Journal of Roentgenology

Volumn 197, Issue 6, 2011, Pages 1369-1374

  Muglia, Valdair F ^a   Westphalen, Antonio C ^b   Wang, Zhen J ^b   Kurhanewicz, John ^b   Carroll, Peter R ^c   Coakley, Fergus V ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

MR spectroscopy; MRI; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL CLASSIFICATION; D AMICO RISK CLASSIFICATION; ENDORECTAL MRI; FOLLOW UP; GLEASON SCORE; GROSS EXTRACAPSULAR EXTENSION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEMINAL VESICLE; TUMOR BIOPSY;

BIOPSY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 82455181485     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.6425     Document Type: Article

References (28)

1. American Cancer Society. Cancer facts and figures 2009. Atlanta, GA: American Cancer Society, 2009
2. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED, eds. Campbell's urology. Philadelphia, PA: Saunders, 1992:1159-1221
3. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271:368-374 (Pubitemid 24037911)
4. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol 1997; 157:2206-2209 (Pubitemid 27208672)
5. Cox J, Amling CL. Current decision-making in prostate cancer therapy. Curr Opin Urol 2008; 18:275-278 (Pubitemid 351489378)
6. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170:1792-1797 (Pubitemid 37254930)
7. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58:843-848 (Pubitemid 34017254)
8. D'Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17:168-172 (Pubitemid 29022390)
9. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco, cancer of the prostate risk assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173:1938-1942 (Pubitemid 40675216)
10. Obek C, Louis P, Civantos F, Soloway MS. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol 1999; 161:494-498, discussion 498-499
11. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 2002; 167:103-111 (Pubitemid 34024511)
12. Shukla-Dave A, Hricak H, Kattan MW, et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 2007; 99:786-793 (Pubitemid 46439567)
13. Joseph T, McKenna DA, Westphalen AC, et al. Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy. Int J Radiat Oncol Biol Phys 2009; 73:665-671
14. McKenna DA, Coakley FV, Westphalen AC, et al. Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy-initial experience. Radiology 2008; 247:141-146
15. Jager GJ, Ruijter ET, van de Kaa CA, et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR 1996; 166:845-852 (Pubitemid 26102064)
16. Stratton KL, Chang SS. Locally advanced prostate cancer: the role of surgical management. BJU Int 2009; 104:449-454
17. Littrup PJ, Williams CR, Egglin TK, Kane RA. Determination of prostate volume with transrectal US for cancer screening. Part II. Accuracy of in vitro and in vivo techniques. Radiology 1991; 179:49-53
18. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965-974
19. D'Amico AV, Whittington R, Malkowicz B, et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol 2000; 164:759-763 (Pubitemid 30637618)
20. Freeman GH, Halton JH. Note on exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 1951; 38:141-149
21. Trabulsi EJ, Valicenti RK, Hanlon AL, et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 2008; 72:1298-1302; discussion 1302-1304
22. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360:2516-2527
23. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002; 53:1111-1116 (Pubitemid 34787844)
24. Hricak H, Wang L, Wei DC, et al. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 2004; 100:2655-2663 (Pubitemid 38715772)
25. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003; 170:S21-S25
26. Rockette HE, Gur D, Metz CE. The use of continuous and discrete confidence judgments in receiver operating characteristic studies of diagnostic imaging techniques. Invest Radiol 1992; 27:169-172
27. González-San Segundo C, Herranz-Amo F, Alvarez-González A, et al. Radical prostatectomy versus external-beam radiotherapy for localized prostate cancer: long-term effect on biochemical control - in search of the optimal treatment. Ann Surg Oncol 2011 Mar 23 [Epub ahead of print]
28. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥ 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58:25-33 (Pubitemid 38010333)